Results 41 to 50 of about 74,341 (223)

Nasal Tuft Cell Markers Are Predictive of Overall Survival in Sinonasal Neuroendocrine and Sinonasal Undifferentiated Carcinomas

International Forum of Allergy &Rhinology, EarlyView.
ABSTRACT Background Sinonasal neuroendocrine carcinoma (SNEC) and sinonasal undifferentiated carcinoma (SNUC) are rare aggressive malignancies with no established prognostic markers. Because features of POU2F3+ small cell lung carcinomas have been identified in both tumors, we evaluated immunostaining for POU2F3, a tuft cell transcription factor, and ...
Nikolina Dioufa, Ricardo V. Bruneto, Jennifer E. Douglas, Nithin D. Adappa, James N. Palmer, Noam A. Cohen, Michael A. Kohanski   +6 more
wiley   +1 more source

Optimization of pharmaceutical research and development by early‐phase assessment of investigational medicinal products

British Journal of Clinical Pharmacology, EarlyView.
Small and mid‐sized pharmaceutical innovators often have limited in‐house health economics and market access expertise, and may struggle to align development strategies of investigational medicinal products with health system needs and payer expectations.
Zoltán Kaló, Attila Imre, Gábor Varga, Sándor Kovács, György Tímár, Balázs Nagy   +5 more
wiley   +1 more source

Inhibition of MDR1 does not sensitize primitive chronic myeloid leukemia CD34⁺ cells to imatinib [PDF]

, 2009
<p><b>Objective:</b> To investigate the interaction of imatinib mesylate (IM) with the clinically relevant adenosine triphosphate-binding cassette efflux transporter MDR1 (ABCB1) in cells from patients with chronic myeloid leukemia (CML)
Holyoake, T.L., Jordanides, N.E., Jorgensen, H.G., Hatziieremia, S., Mountford, J.C., Joanne C. Mountford, Tessa L. Holyoake, Heather G. Jørgensen, Sophia Hatziieremia, Niove E. Jordanides   +9 more
core   +1 more source

From anthelmintic to neuro‐oncology: A systematic review of mebendazole repurposing for brain tumour therapy

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim Mebendazole (MBZ), a benzimidazole anthelmintic with established clinical use, has emerged as a repurposing candidate for primary brain tumours due to its multimodal anticancer actions and central nervous system penetrance. This systematic review synthesizes preclinical and clinical evidence evaluating MBZ's efficacy, mechanisms of action ...
Ciara B. Blum, Milli McMenamin, Tessa Khoo, John M. Edwin, Prathibha Jose, Liam A. O’Callaghan   +5 more
wiley   +1 more source

Imatinib-Induced Changes in Protein Expression and ATP-Binding Affinities of Kinases in Chronic Myelocytic Leukemia Cells [PDF]

, 2019
Kinases are crucial components in numerous cell signaling pathways. Aberrant expression and activation of protein kinases are known to be accompanied by many types of cancer, and more than 30 small-molecule kinase inhibitors have been approved by the ...
Lei Guo (36221), Weili Miao, Yinsheng Wang, Weili Miao (3131388), Guo, Lei, Miao, Weili, Lei Guo, Wang, Yinsheng, Yinsheng Wang (8699)   +8 more
core   +1 more source

Adaptive imatinib regimens can mitigate cumulative toxicity while sustaining hemodynamic benefit: A model‐based simulation of the positioning imatinib for pulmonary arterial hypertension trial

British Journal of Clinical Pharmacology, EarlyView.
ABSTRACT Aims Imatinib improves hemodynamics in pulmonary arterial hypertension (PAH), but dose‐dependent toxicity has limited its clinical development. We aimed to quantify the dose–efficacy–toxicity relationship and evaluate alternative dosing strategies using data from the PIPAH trial.
Medhat M. Said, Robert B. de Mooij, Dian Jiao, Reitze J. Ovelgonne, Rami Biram, Juan Delgado‐SanMartin, Alexander M. K. Rothman, Sofia S. Villar, Andreas A. Roussakis, Jurjan Aman, Ron A. A. Mathôt, Eleonora L. Swart, Martin R. Wilkins, Imke H. Bartelink   +13 more
wiley   +1 more source

Effect of astaxanthin in imatinib mesylate-induced cardiotoxicity

Acta Medica Alanya, 2020
Aim: Imatinib mesylate is a tyrosine kinase inhibitor and is approved as a standard first-line therapy of chronic myeloid leukemia. Oxidative stress, as well as intracellular calcium overload and mitochondrial dysfunction, play an important role in ...
İshak Suat Övey, Can Ramazan Öncel
doaj  

In vitro effects of imatinib mesylate on radiosensitivity and chemosensitivity of breast cancer cells

BMC Cancer, 2010
Background Breast cancer treatment is based on a combination of adjuvant chemotherapy followed by radiotherapy effecting intracellular signal transduction. With the tyrosine kinase inhibitors new targeted drugs are available.
Weigel Marion T, Dahmke Linda, Schem Christian, Bauerschlag Dirk O, Weber Katrin, Niehoff Peter, Bauer Maret, Strauss Alexander, Jonat Walter, Maass Nicolai, Mundhenke Christoph   +10 more
doaj   +1 more source

Imatinib-induced hepatitis treated by corticosteroids in a patient with metastatic gastrointestinal stromal tumor [PDF]

Yeungnam University Journal of Medicine, 2019
Imatinib mesylate is currently used as the first-line treatment for metastatic gastrointestinal stromal tumors (GISTs). Imatinib-induced hepatotoxicity in patients with GIST is very rare.
Min Kyu Kang, Heon Ju Lee, Joon Hyuk Choi   +2 more
doaj   +1 more source

Bone marrow‐like viscosity affects imatinib resistance in chronic myeloid leukemia

Biotechnology Progress, EarlyView.
Physical cues such as microenvironmental viscosity have been recognized as important regulators in controlling cell functions. However, even though the bone marrow (BM) is a viscous tissue in which cells respond mechanically to both the matrix stiffness and the viscosity of surrounding fluid, the impact of microenvironmental viscosity on imatinib (IM ...
Tianjiao Zeng, Huajian Chen, Man Wang, Toru Yoshitomi, Naoki Kawazoe, Yingnan Yang, Guoping Chen   +6 more
wiley   +1 more source